A Memphis-based biotech company announced in early August a partnership with a federal agency to work on a temperature stable, oral vaccine against two strains of the influenza virus. US Biologic, known for its proprietary oral-delivery platform OrisBio, produces oral vaccines and therapeutics, which are currently being used in animals to prevent zoonotic diseases. The company describes its platform as “safe, efficacious, and cost-effective for other infectious diseases with pandemic potential.”
BARDA DRIVe partners with US Biologic, Inc. in the development of an oral vaccine for pandemic influenza
The U.S. DHHS Biomedical Advanced Research and Development Authority (BARDA) Division of Research Innovation and Ventures (DRIVe) is partnering with US Biologic Inc. to advance the development of an oral vaccine for the influenza virus. This partnership aligns with the goals of BARDA DRIVe’s Beyond the Needle program: to make vaccines and therapeutics easier to administer and more widely available, without the need for needles, syringes, vials, and cold-chain distribution burdens.
"US Biologic envisions a world where everyone has equitable access to lifesaving technologies," stated Mason Kauffman, CEO of US Biologic. "Our mission is to reduce disease through predictive analytics and orally delivered vaccines and therapeutics delivered to the home. The SAMS Coalition will help impact policy to rebuild American infrastructure and strategic product stockpiles, and US Biologic proudly supports efforts to strengthen our responses to future pandemic threats."
Researchers at the USDA’s Agricultural Research Service and US Biologic, Inc., have developed an oral solution to an antibiotic alternative that fights against poultry coccidiosis, which costs the poultry industry $3.5B in annual losses worldwide.
"Major League" Researcher: Trela worked an internship at US Biologic this summer, holds a 4.0 GPA in biomedical engineering.
As part of his major, the shortstop needed an internship and was eager to complete one close to his second "home." The senior, through Bumgardner, was connected with Dr. Jolieke van Oosterwijk, Chief Science Officer with an innovative biotech company called US Biologic located in downtown Memphis. The disease prevention company develops oral vaccines to address the world's greatest health challenges. After meeting with van Oosterwijk, Trela knew it would be a great fit. He began working on experiments surrounding animal-borne diseases and quickly got into the groove of hands-on work.
Every January, planes dump one million small plastic packets covered in fishmeal crumbles along the Texas-Mexico border. When the sharp teeth of feral dogs or coyotes pierce the plastic, a liquid rabies vaccine squirts into their mouths.
On a balmy day in late June, Scott Williams waits for a white-footed mouse (Peromyscus leucopus) to fall asleep. Williams, a wildlife biologist with the Connecticut Agricultural Experiment Station in New Haven, has just transferred the animal from a trap to a plastic bag containing a cotton ball doused in anaesthetic. As soon as the mouse's breathing slows to one breath per second, Williams will take it out, draw blood, weigh it, put an ear tag on it for identification and check the animal for ticks, saving any that are engorged with blood. He must work quickly. The mouse will wake up in about two minutes, and she might be grumpy.
Months after a U.S. Congress–mandated working group sounded the alarm about tickborne illnesses and urged more federal action and money, the National Institutes of Health (NIH) is readying a strategic plan for these diseases. Last week it also, serendipitously, issued a rare solicitation for prevention proposals in tickborne diseases. The new pot of money, $6 million in 2020, represents a significant boost; NIH spent $23 million last year on Lyme disease, by far the most common tickborne illness, within $56 million devoted to tickborne diseases overall.
Kirby Stafford, Connecticut’s state entomologist, knows only one surefire way to reduce tick populations enough to cut Lyme disease rates: killing deer. Otherwise, he says, “very little by itself really reduces tick numbers enough.”
But in some Connecticut neighborhoods Stafford has been testing a new strategy, one he hopes might show real promise after years of stymied efforts to drive new Lyme infections down: a vaccine for mice.
US Biologic Broadens Intellectual Property Platform in Prevention of Zoonotic Disease
US Biologic, a leading oral vaccine and therapeutic delivery company, today announced that the United States Patent and Trademark Office has issued U.S. Patent #1065360 entitled “Composition & Method for Reducing Zoonotic Infectious Diseases.” The patent extends the US Biologic OrisBio™ oral-delivery technology platform in the creation of orally delivered vaccines.
Mason Kauffman of US Biologic on WKNO TV's The Spark
The theme of The SPARK May 2020 is "Looking Out for Public Health." Jeremy C. Park interviews Mason Kauffman of US Biologic, a Memphis-based company delivering disease prevention by providing orally delivered vaccines to address the world's great health challenges.
CAES Announces Field Trials Showing Impact of a Variety of Delivery Mechanisms for Zoonotic Disease Control
The Connecticut Agricultural Experiment Station (CAES) and US Biologic, Inc. announce today the publication of field trials showing the impact of delivery mechanisms to enhance future animal-borne (aka: zoonotic) disease control programs.
US Biologic/CAES Report Field Trials of Orally Delivered Anti-Lyme Vaccine Targeting the Field Mouse
The Connecticut Agricultural Experiment Station (CAES) and US Biologic announced the publication of field trials showing the effectiveness of the delivery of an orally-delivered anti-Lyme vaccine targeting the major wildlife source of Lyme disease, the white-footed mouse.
The condition in canines is rising in states traditionally not considered to be high-risk, suggesting human endangerment may also be increasing in these areas.
Lyme disease in dogs has become increasingly common in the Northeast and has moved into U.S. regions not historically considered endemic.
“The Centers for Disease Control and Prevention is investigating a tick that is spreading widely across the United States.
Nine states have reported finding the Asian longhorned tick, which is known to carry a variety of pathogens. The CDC said late last week it is investigating how the tick could impact the U.S.”
“Practitioners in both veterinary and human medicine must remain aware of the changing geography of ticks and associated vector-borne diseases. The discovery of the Asian tick H longicornis in New Jersey and Virginia should be an important reminder of the fact that ‘ticks and tickborne pathogens do not recognize international boundaries.’ Thus, ‘a robust international disease monitoring network’ is needed to protect both human and animal health from both known and emerging tick-borne diseases.”
US BIOLOGIC Note: This summary is based on a review article published in the June 2018 issue of Veterinary Sciences and authored by Dr. Stephen Wikel, US BIOLOGIC‘s senior science advisor.
“This really bites and sucks. The tick population continues to grow, Lyme Disease continues to spread, and now according to a recently released analysis from Quest Diagnostics Lyme Disease can be found in all 50 states plus Washington, D.C.”
“For the first time in 50 years, a new tick species has arrived in the United States — one that in its Asian home range carries fearsome diseases. The Asian long-horned tick, Haemaphysalis longicornis, is spreading rapidly along the Eastern Seaboard. It has been found in seven states and in the heavily populated suburbs of New York City.”
“The spread of Lyme disease has followed that of deer ticks. The incidence of Lyme has more than doubled over the past two decades. In 2016, federal health officials reported 36,429 new cases, and the illness has reached far beyond endemic areas in the Northeast to points west, south and north.”
“Other ticks, such as lone star ticks, carry diseases, too, including Rocky Mountain spotted fever, ehrlichiosis and tularemia; yet we know even less about where these ticks are or how their populations are changing.”